Loading clinical trials...
Loading clinical trials...
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration.
The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
January 1, 2007
Primary Completion Date
May 1, 2008
Completion Date
May 1, 2008
Last Updated
November 28, 2012
291
ACTUAL participants
Anecortave Acetate 15 mg sterile suspension
DRUG
Anecortave Acetate Vehicle
OTHER
Lead Sponsor
Alcon Research
NCT05913063
NCT07446582
NCT06779773
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions